At ASH, positive news for Terns, Kura leukemia treatments

The American Society of Hematology (ASH) meeting is a significant event in the world of medicine, where groundbreaking research and advancements in the field of hematology are unveiled. This year’s ASH meeting, although initially sunny and promising, was plagued by rainy weather, prompting some to suggest that the event should permanently relocate to San Diego for more favorable weather conditions.

One of the key highlights of the ASH meeting was the presentation by Terns Pharmaceuticals on their targeted leukemia drug, which showed promising results in advanced-stage patients. The drug demonstrated high molecular response rates, indicating its potential as a successor to Novartis’ blockbuster leukemia drug. The update from Terns Pharmaceuticals generated significant interest and excitement among attendees at the meeting.

However, access to detailed information on Terns Pharmaceuticals’ study is restricted to STAT+ subscribers. The exclusive content provides in-depth analysis and coverage of the biotech sector, making it a valuable resource for professionals in the field. Subscribing to STAT+ unlocks a wealth of information and insights that can benefit researchers, clinicians, and investors alike.

For those interested in delving deeper into the latest developments in hematology and biotechnology, subscribing to STAT+ is highly recommended. By gaining access to exclusive articles and analyses, subscribers can stay informed and up to date on the latest trends and advancements in the industry. Don’t miss out on the opportunity to expand your knowledge and stay ahead of the curve by subscribing to STAT+ today.